There's an odd phenomenon in dealmaking: plenty of R&D stage deals; plenty of deals for marketable products; relatively few deals in the middle.
There's good bureaucratic logic for this inverted bell curve. An R&D stage deal carries relatively little risk for the R&D...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?